DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on December 6, 2006; DOI: 10.1124/dmd.106.013243


0090-9556/07/3503-419-427$20.00
DMD 35:419-427, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.106.013243v1
35/3/419    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Senekeo-Effenberger, K.
Right arrow Articles by Tukey, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Senekeo-Effenberger, K.
Right arrow Articles by Tukey, R. H.

Expression of the Human UGT1 Locus in Transgenic Mice by 4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic Acid (WY-14643) and Implications on Drug Metabolism through Peroxisome Proliferator-Activated Receptor {alpha} Activation

Kathy Senekeo-Effenberger, Shujuan Chen, Erin Brace-Sinnokrak, Jessica A. Bonzo, Mei-Fei Yueh, Upendra Argikar, Jenny Kaeding, Jocelyn Trottier, Rory P. Remmel, Joseph K. Ritter, Olivier Barbier, and Robert H. Tukey

Laboratory of Environmental Toxicology, Department of Chemistry & Biochemistry and Department of Pharmacology, University of California, San Diego, La Jolla, California (K.S-E., S.C., E.B-S., J.A.B., M-F.Y., R.H.T.); Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (U.A., R.P.R.); Molecular Endocrinology and Oncology Research Center, CHUL Research Center and the Faculty of Pharmacy, Laval University, Québec, Québec, Canada (J.K., J.T., O.B.); and Department of Pharmacology and Toxicology, Virginia Commonwealth University, Medical College of Virginia, Richmond, Virginia (J.K.R.)

The UDP-glucuronosyltransferase (UGT) 1A genes in humans have been shown to be differentially regulated in a tissue-specific fashion. Transgenic mice carrying the human UGT1 locus (Tg-UGT1) were recently created, demonstrating that expression of the nine UGT1A genes closely resembles the patterns of expression observed in human tissues. In the present study, UGT1A1, UGT1A3, UGT1A4, and UGT1A6 have been identified as targets of the peroxisome proliferator-activated receptor (PPAR) {alpha} in human hepatocytes and Tg-UGT1 mice. Oral administration of the PPAR{alpha} agonist 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (pirinixic acid, WY-14643) to Tg-UGT1 mice led to induction of these proteins in either the liver, gastrointestinal tract, or kidney. The levels of induced UGT1A3 gene transcripts in liver and UGT1A4 protein in small intestine correlated with induced lamotrigine glucuronidation activity in these tissues. With UGT1A3 previously identified as the major human enzyme involved in human C24-glucuronidation of lithocholic acid (LCA), the dramatic induction of liver UGT1A3 RNA in Tg-UGT1 mice was consistent with the formation of LCA-24G in plasma. Furthermore, PPAR-responsive elements (PPREs) were identified flanking the UGT1A1, UGT1A3, and UGT1A6 genes by a combination of site-directed mutagenesis, specific binding to PPAR{alpha} and retinoic acid X receptor {alpha}, and functional response of the concatenated PPREs in HepG2 cells overexpressing PPAR{alpha}. In conclusion, these results suggest that oral fibrate treatment in humans will induce the UGT1A family of proteins in the gastrointestinal tract and liver, influencing bile acid glucuronidation and first-pass metabolism of other drugs that are taken concurrently with hypolipidemic therapy.


Address correspondence to: Dr. Robert H. Tukey, 9500 Gilman Dr., Leichtag Biomedical Research Building, University of California, San Diego, La Jolla, CA 92093-0722. E-mail: rtukey{at}ucsd.edu




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
N. Nguyen, J. A. Bonzo, S. Chen, S. Chouinard, M. J. Kelner, G. Hardiman, A. Belanger, and R. H. Tukey
Disruption of the Ugt1 Locus in Mice Resembles Human Crigler-Najjar Type I Disease
J. Biol. Chem., March 21, 2008; 283(12): 7901 - 7911.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
A. Koch, B. Konig, G. I. Stangl, and K. Eder
PPAR{alpha} Mediates Transcriptional Upregulation of Novel Organic Cation Transporters-2 and -3 and Enzymes Involved in Hepatic Carnitine Synthesis
Experimental Biology and Medicine, March 1, 2008; 233(3): 356 - 365.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
M. Osabe, J. Sugatani, T. Fukuyama, S.-i. Ikushiro, A. Ikari, and M. Miwa
Expression of Hepatic UDP-Glucuronosyltransferase 1A1 and 1A6 Correlated with Increased Expression of the Nuclear Constitutive Androstane Receptor and Peroxisome Proliferator-Activated Receptor {alpha} in Male Rats Fed a High-Fat and High-Sucrose Diet
Drug Metab. Dispos., February 1, 2008; 36(2): 294 - 302.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.